Inventiva ADR(IVA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 15 at 8:57 AM ET (Korea 9/15 21:57)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -2.84 | Insider Own | 7.56% | Shs Outstand | 236.2M | Perf Week | -18.83% |
| Market Cap | 0.92B | Forward P/E | - | EPS next Y | -1.14% | Insider Trans | - | Shs Float | 218.4M | Perf Month | -15.65% |
| Enterprise Value | 0.87B | PEG | - | EPS next Q | -0.38 | Inst Own | 29.26% | Short Float | 1.69% | Perf Quarter | 0.78% |
| Income | -0.40B | P/S | 187.06 | EPS this Y | 63.83% | Inst Trans | 12.43% | Short Ratio | 3.36 | Perf Half Y | -35.23% |
| Sales | 0.00B | P/B | - | EPS next 5Y | 60.01% | ROA | -192.65% | Short Interest | 3.68M | Perf YTD | -16.56% |
| Book/sh | -0.18 | P/C | 7.86 | EPS past 3/5Y | -15.85% -13.59% | ROE | - | 52W High | -51.39% ($7.98) | Perf Year | -30.84% |
| Cash/sh | 0.49 | P/FCF | - | Sales past 3/5Y | -26.61% 64.18% | ROIC | - | 52W Low | 15.82% ($3.35) | Perf 3Y | -4.67% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 14.8% | Gross Margin | 33.27% | Volatility(W/M) | 7.09% 5.01% | Perf 5Y | -71.17% |
| Dividend TTM | - | EV/Sales | 177.5 | Sales Y/Y TTM | -50.8% | Oper. Margin | -3159.89% | ATR (14) | 0.25 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.15 | EPS Q/Q | - | Profit Margin | -8165.65% | RSI (14) | 27.96 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.15 | Sales Q/Q | - | SMA20 | -15.96% ($4.62) | Beta | 0.78 | Target Price | $13.83 |
| Payout | - | Debt/Eq | - | Earnings | 2026/9/25 | SMA50 | -14.86% ($4.56) | Rel Volume | 1.36 | Prev Close | $4.02 |
| Employees | 77 | LT Debt/Eq | - | EPS/Sales Surpr. | -82.55% -70.33% | SMA200 | -23.55% ($5.08) | Avg Volume(3M) | 1.10M | Price | $3.88 |
| IPO | 2020/7/10 | Option/Short | Yes/Yes | Trades | 4655 | Volume | 1,493,404 | Change | -3.48% |
Company
IVA is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Inventiva is a clinical-stage biotech company developing treatments for metabolic and fibrotic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Its lead candidate, lanifibranor—an oral pan-PPAR (peroxisome proliferator-activated receptor) agonist that activates three receptor subtypes simultaneously—is being evaluated in a global Phase 3 clinical trial and features a differentiated mechanism of action that simultaneously targets anti-fibrosis, anti-inflammation, and metabolic improvement.
Over the past 1 year, on the lower side
51% below its 1-year high.
Upcoming eventsD-$ until next earnings
Scheduled for September 25
IVA has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +63.8% this year.
Tap to view numbers
The price looks about right
Trading at - times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -4.7% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 29.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
SURI 0.02%
DBEZ 0.00%
ISCF 0.00%
APIE 0.00%
GTPE 0.00%Special products that amplify (leveraged) or invert this single stock. They decay quickly and are not for long-term holding.
BLCR 6.8B
CGMS 5.4B
CGSD 2.6B
BFLX 2.1B
XHLF 2.0BIt ranks #4 in the industry
Based on market cap of $917M.
IVA $917M PER -
VRTX $132B PER 30.2
REGN $82B PER 19.6
ARGX $62B PER 37.8
FAQ
What kind of company is IVA?
IVA belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of IVA?
The market cap of IVA is approximately $917M, ranking 2,710 within its sector.
What is the 52-week high and low for IVA?
IVA has recorded a 52-week high of $7.98 and a low of $3.35.
